CD5 and lymphoma: So far, there have been a few of phase I studies (NCT03081910, NCT04689659, NCT04004637) in regard to the CAR-T cells targeting CD5 or CD7 to treat relapsed/refractory T-lymphocytic leukemia/lymphoma, but with tumor recurrence [52–54].